Aim: To experimentally assess activity and safety of anti-anthrax intravenous immunoglobulin manufactured on standard technology.
Materials And Methods: Plasma from selected donors vaccinated with combined anthrax vaccine was tested by enzyme immunoassay. Samples of plasma with increased titer of anti-anthrax antibodies were merged in one manufacturing load and fractionated in ethanol at negative temperature according to standard technology.